c-MET is a protein on the surface of cells that acts as a receptor, receiving signals that tell cells to grow, move, and survive. In healthy tissue, c-MET plays a controlled role in wound healing and organ development. In cancer, the system goes haywire: mutations, extra copies of the gene, or overproduction of the protein can lock c-MET into an always-on state, flooding tumor cells with growth and survival signals that fuel the disease. Understanding how c-MET drives cancer has become a major focus in oncology, particularly because drugs that target this receptor are now approved and in wide use for certain tumor types.
What c-MET Does in Healthy Cells
c-MET is a receptor tyrosine kinase, which is a fancy way of saying it sits on the outside of a cell, waits for a specific chemical messenger to dock with it, and then triggers a cascade of activity inside the cell. The messenger it responds to is called hepatocyte growth factor, or HGF. When HGF binds to c-MET, it activates programs that promote cell growth, movement, and the formation of new blood vessels. These are all things your body needs during embryonic development, tissue repair after an injury, and liver regeneration.
The physical structure of c-MET helps explain how it works. The part of the receptor that sticks outside the cell has a large region at the front end that binds HGF, adopting a shape called a beta-propeller fold, while the trailing portion contains a series of structural domains that help position the receptor correctly on the cell surface.1PubMed Central. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor The part inside the cell contains the enzymatic machinery that kicks off signaling. Under normal conditions, once c-MET has done its job, the cell tags the receptor for destruction and breaks it down, keeping the signal brief and controlled. That cleanup mechanism turns out to be one of the critical points where things go wrong in cancer.
How c-MET Becomes an Oncogenic Driver
Healthy c-MET signaling is tightly regulated. Cancer hijacks this system through three main routes: gene mutations, gene amplification (extra copies of the c-MET gene), and protein overexpression (too much c-MET protein on the cell surface). Each of these routes leads to the same basic problem: persistent, uncontrolled c-MET activation that keeps pushing cells to grow, divide, and spread.
One of the most well-studied mutations involves a section of the gene called exon 14. When mutations cause the cell to skip over exon 14 during the process of reading the gene, the resulting c-MET protein is missing a chunk of its internal structure called the juxtamembrane domain. That missing piece normally contains a landing site for a protein called CBL, whose job is to tag c-MET for destruction. Without that tag, the mutant receptor accumulates on the cell surface instead of being broken down, staying active far longer than it should.2PubMed Central. MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling The result is constitutive activation, meaning the signaling pathway is essentially stuck in the “on” position.3PubMed Central. Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression
Gene amplification takes a different approach to the same outcome. Instead of altering the receptor’s structure, the cell simply ends up with too many copies of the MET gene, which leads to an overabundance of c-MET protein on the surface. One diagnostic challenge here is distinguishing true focal amplification, where the MET gene itself has been duplicated, from polysomy, where the entire chromosome carrying MET has been duplicated. The distinction matters for treatment decisions, and simple copy-number counting alone is not enough to tell them apart.4PubMed Central. Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches
Inherited mutations in c-MET also exist, though they are rare. Germline missense mutations in the tyrosine kinase domain of the MET gene cause hereditary papillary renal carcinoma, a condition that predisposes people to developing multiple kidney tumors on both sides.5PubMed. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene This is one of the clearest examples of c-MET acting as a direct hereditary cancer driver.
The Signaling Pathways c-MET Switches On
When c-MET is inappropriately activated in a cancer cell, it does not just flip one switch. It lights up multiple signaling highways at once. These include the PI3K/AKT pathway (which promotes cell survival and blocks programmed cell death), the Ras/MAPK pathway (which drives cell proliferation), and the Wnt/β-catenin, JAK/STAT, and SRC pathways, all of which contribute to tumor growth, migration, and invasion.6PubMed Central. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities Additional effectors like PLCγ further broaden the downstream impact.7PubMed Central. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer
This multi-pathway activation is part of what makes c-MET-driven cancers aggressive. A cell receiving all these simultaneous “go” signals is being told to grow, to avoid dying, to move, and to remodel its surroundings, all at the same time. It also means that blocking just one downstream pathway may not be enough to shut the system down, since the others can compensate. This redundancy is one of the reasons that therapeutic strategies have focused on hitting c-MET itself rather than trying to block each downstream pathway individually.
How c-MET Promotes Spread and Drug Resistance in Tumors
Beyond just making tumor cells grow faster, c-MET plays a specific and damaging role in metastasis, the process by which cancer spreads from its original site to distant organs. One of the key mechanisms is something called epithelial-mesenchymal transition, or EMT. In simple terms, EMT is a process where cells that normally sit still and stick to their neighbors transform into cells that can detach and migrate. It is a normal part of embryonic development, but in cancer it enables tumor cells to break free and invade other tissues.
Research in colorectal cancer has shown that overexpression of c-MET promotes EMT along with invasion, migration, and resistance to chemotherapy drugs.8PubMed. cMET promotes metastasis and epithelial-mesenchymal transition in colorectal carcinoma by repressing RKIP Similar findings appear in bladder cancer, where the HGF/c-MET signaling axis drives EMT through a feedback loop that shifts cellular markers from an “attached” profile to a “mobile” one.9PubMed Central. Adaptor protein CRK induces epithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF/c-Met feedback loop In gastric cancer, c-MET cooperates with another receptor pathway to activate a signaling chain that triggers EMT, and blocking c-MET partially reversed both the molecular shift and the increased ability of cells to spread.10Translational Oncology. The Chemokine Receptor CXCR4 and c-MET Cooperatively Promote Epithelial-Mesenchymal Transition in Gastric Cancer Cells
The fact that c-MET promotes both growth and spread, and that it does so across many different cancer types, is part of why oncologists have spent decades working to target it.
Which Cancers Are Driven by c-MET
c-MET abnormalities crop up across a wide range of tumor types, but the best-characterized clinical setting is non-small cell lung cancer, or NSCLC. Exon 14 skipping mutations are found in roughly 1 to 4 percent of NSCLC cases.11PubMed Central. MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience That may sound like a small fraction, but given that NSCLC is the most common form of lung cancer worldwide, even a few percent translates into a large number of patients. Screening for these mutations has become standard practice for first-line treatment decisions, particularly because MET-mutated tumors often respond poorly to immunotherapy alone.
Gastrointestinal cancers, including stomach and colorectal cancers, also frequently show abnormal HGF/c-MET signaling, and elevated c-MET activity tends to track with worse outcomes in those diseases.12PubMed. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives As mentioned earlier, hereditary papillary renal carcinoma is driven by germline MET mutations. Beyond these, c-MET alterations have been implicated in hepatocellular carcinoma (liver cancer), pancreatic cancer, bladder cancer, head and neck cancers, and several others. The protein’s involvement across so many cancer types underscores the fundamental nature of the pathways it controls.
The Tumor Microenvironment and the HGF/c-MET Feedback Loop
c-MET does not just act within tumor cells. It plays a central role in the cross-talk between tumors and their surrounding environment. Tumors are not isolated clumps of malignant cells; they exist in a neighborhood of supportive cells, blood vessels, and structural tissue collectively called the tumor microenvironment. Among the key players in this neighborhood are cancer-associated fibroblasts, or CAFs, which are stromal cells that have been co-opted by the tumor.
CAFs produce HGF, which activates c-MET on tumor cells. Those tumor cells, in turn, secrete growth factors that push CAFs to produce even more HGF, creating a self-reinforcing feedback loop.13PubMed Central. Activation of the HGF/c-Met axis in the tumor microenvironment: a multispecies model Many cancer types show this pattern, where the tumor essentially trains its local environment to keep feeding it pro-growth signals.14PubMed. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions
Research in pancreatic cancer has identified one specific molecule, tenascin-C, that acts as a key middleman in this loop. When HGF from the stroma activates c-MET on pancreatic cancer cells, those cells ramp up production of tenascin-C, which then further activates the surrounding stroma, sustaining the cycle. Blocking the HGF/c-MET axis in co-culture experiments reduced fibroblast activation, suggesting that interrupting this loop could weaken the tumor’s support system.15PubMed Central. HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer
Crosstalk With Other Receptors
c-MET does not operate in isolation on the cell surface. It interacts, sometimes physically, with other receptor tyrosine kinases, and these interactions add another layer of complexity to how it drives cancer. In bladder cancer, for instance, c-MET has been shown to interact with receptors including RON, EGFR, Axl, and PDGFR-α. Activated c-MET can directly bind to and activate the RON receptor through a process called heterodimerization, triggering signaling through both receptors simultaneously. The relationship with EGFR is similarly direct. By contrast, the connections to Axl and PDGFR-α are indirect, operating through shared downstream signaling rather than physical contact between the receptors.16Advances in the Scientific Evaluation of Bladder Cancer and Molecular Basis for Diagnosis and Treatment. The Crosstalk of c-MET with Related Receptor Tyrosine Kinases in Urothelial Bladder Cancer
This receptor crosstalk has practical consequences. When one pathway is blocked by a drug, another activated receptor can sometimes pick up the slack and keep the cancer growing. This is one reason that c-MET amplification has become a major resistance mechanism against EGFR-targeted drugs in lung cancer, a topic we turn to next.
c-MET as a Resistance Mechanism Against EGFR Drugs
One of the most clinically significant roles c-MET plays in cancer has nothing to do with being the primary driver of the tumor. Instead, it acts as an escape route. In NSCLC patients whose tumors are driven by EGFR mutations, targeted EGFR inhibitors like osimertinib are highly effective, often for months or years. But tumors eventually find ways to keep growing despite the drug. c-MET amplification has emerged as one of the most common mechanisms of acquired resistance, detected in roughly a quarter of NSCLC tumors that stop responding to osimertinib.17PubMed Central. Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
What happens is that even while EGFR is being shut down by the drug, the tumor ramps up MET signaling as a bypass route, reactivating many of the same survival and growth pathways through a different receptor. This has made MET amplification one of the most frequent off-target resistance mechanisms in the EGFR-inhibitor setting.18PubMed Central. The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications The clinical takeaway is that when an EGFR-driven lung cancer progresses on treatment, testing for MET amplification is now a standard next step, because adding a MET inhibitor may restore drug sensitivity.
Drugs That Target c-MET
Therapeutic strategies aimed at c-MET fall into a few broad categories. The most established are small-molecule tyrosine kinase inhibitors, or TKIs, which work by physically blocking the part of the receptor inside the cell that triggers signaling. These drugs are further divided by how they bind to the receptor. Type I inhibitors, including capmatinib, tepotinib, and savolitinib, plug into the receptor’s active form. Type II inhibitors, including cabozantinib and foretinib, bind to the inactive form of the receptor and extend into a different structural pocket. A third class of non-competitive inhibitors binds outside the main pocket entirely.19PubMed Central. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
Capmatinib and tepotinib are the drugs that have advanced furthest clinically for MET exon 14-mutated NSCLC, and both have shown activity against brain metastases, a notoriously difficult problem. In patients with MET exon 14-mutated NSCLC who had neurologically stable brain metastases, capmatinib and tepotinib achieved intracranial response rates of about 54 percent and 67 percent, respectively.20Cancer Treatment Reviews. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape Preclinical work on tepotinib showed that the drug achieved brain concentrations several times higher than plasma concentrations in animal models, and it induced pronounced tumor regression in brain-implanted tumors regardless of whether the blood-brain barrier was leaky.21PubMed. Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases
Beyond small molecules, antibody-drug conjugates represent a newer approach. Telisotuzumab vedotin (Teliso-V) is a drug that pairs an antibody targeting c-MET on the cell surface with a potent cell-killing payload. The antibody delivers the payload directly to cells overexpressing c-MET. What makes this approach interesting is that, unlike small-molecule inhibitors, it showed preclinical activity in cells overexpressing c-MET regardless of whether the MET gene itself was amplified, broadening the potential patient population.22Clinical Cancer Research. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
When MET Inhibitors Stop Working
As with most targeted cancer therapies, resistance to MET inhibitors eventually develops. The patterns of resistance are revealing and have practical implications for how patients are treated after their tumor progresses. In laboratory studies testing eight different MET inhibitors, secondary mutations clustered at predictable sites within the receptor. Type I inhibitors, which bind the active form of MET, tended to produce resistance mutations at positions D1228 and Y1230. Type II inhibitors, which bind the inactive form, produced resistance at different sites, L1195 and F1200. Critically, mutations that conferred resistance to type I drugs generally remained sensitive to type II drugs, and vice versa.23PubMed. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
This reciprocal sensitivity pattern is genuinely useful for treatment sequencing. If a patient’s tumor develops resistance to a type I MET inhibitor like capmatinib, switching to a type II inhibitor like cabozantinib may still be effective, and the other way around. It is one of the more encouraging aspects of the MET-targeting landscape and a rare case where understanding the resistance mechanism immediately suggests a practical clinical solution.
How c-MET Alterations Are Detected
Identifying c-MET abnormalities in a patient’s tumor matters for treatment selection, but testing is not entirely straightforward. Fluorescence in situ hybridization, or FISH, remains the standard method for detecting MET amplification. It works by using fluorescent probes that physically light up the gene under a microscope, allowing pathologists to count copies. Next-generation sequencing, or NGS, offers a broader alternative that can detect not just amplification but also point mutations and exon 14 skipping alterations in a single test.24PubMed Central. Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization
However, the two methods do not always agree. FISH defines amplification using a ratio of MET copies to a reference point on the same chromosome, while NGS-based definitions typically use an absolute gene copy-number threshold. In one clinical study, both methods were used to assess MET amplification before MET inhibitor treatment, with FISH using a ratio cutoff and NGS using a copy-number cutoff of five or more.25PubMed Central. MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors The lack of universally agreed-upon NGS cutoffs remains an open challenge. For patients, the practical implication is that a negative result on one test does not necessarily mean a negative on the other, and some oncologists use both when MET-driven disease is suspected.
Combining MET Inhibitors With Immunotherapy
One of the more active areas of research involves pairing c-MET inhibitors with immune checkpoint drugs, particularly those that block PD-1 or PD-L1. The rationale is that c-MET signaling does not just promote tumor growth directly; it also helps tumors evade the immune system. By shutting down c-MET, the idea is to make the tumor more visible and vulnerable to immune attack.
Evidence from multiple preclinical models supports this approach. In pancreatic cancer mouse models, combining MET inhibition with PD-1/PD-L1 blockade produced significant benefits over either therapy alone.26PubMed Central. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy In liver cancer models, the combination of capmatinib with an anti-PD-1 antibody enhanced the number and activity of cancer-killing immune cells within the tumor while reducing immune-suppressive cells. This combination even outperformed a pairing with the type II inhibitor cabozantinib in a model that was already resistant to PD-1 blockade alone.27PubMed Central. Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma A review of both clinical and preclinical evidence has suggested that targeting c-MET alongside immunotherapy is particularly promising in tumors that also show elevated PD-L1 expression.28PubMed Central. Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion
This intersection of c-MET biology and immunology is reshaping how researchers think about the receptor. It is no longer just a growth signal; it is an active participant in helping tumors hide from the immune system, and dismantling that shield could make existing immunotherapies work better for a broader group of patients.